Asa Gold & Precious Metals LTD Has Cut Its Royal Gold (RGLD) Holding; Vtv Therapeutics – Class A (VTVT) SI Decreased By 23.9%

Royal Gold, Inc. (NASDAQ:RGLD) Logo

Asa Gold & Precious Metals Ltd decreased Royal Gold Inc (RGLD) stake by 13.16% reported in 2018Q3 SEC filing. Asa Gold & Precious Metals Ltd sold 25,000 shares as Royal Gold Inc (RGLD)’s stock rose 6.35%. The Asa Gold & Precious Metals Ltd holds 165,000 shares with $12.72M value, down from 190,000 last quarter. Royal Gold Inc now has $5.50 billion valuation. The stock increased 0.70% or $0.58 during the last trading session, reaching $83.94. About 62,981 shares traded. Royal Gold, Inc. (NASDAQ:RGLD) has declined 4.56% since January 11, 2018 and is downtrending. It has underperformed by 4.56% the S&P500. Some Historical RGLD News: 27/03/2018 – Royal Gold Closes Below 200-Day Moving Average: Technicals; 30/05/2018 – Royal Gold Announces Third Quarter Dividend; 09/04/2018 – Royal Gold Provides Update on its Fiscal 2018 Third Quarter; 09/04/2018 – ROYAL GOLD SAYS SOME DELIVERIES WILL BE DEFERRED TO LATER DATE; 28/03/2018 – ROYAL GOLD INC RGLD.O : BMO RAISES TARGET PRICE TO $102 FROM $100; 02/05/2018 – ROYAL GOLD 3Q REV. $116.0M, EST. $112.9M

Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) had a decrease of 23.9% in short interest. VTVT’s SI was 869,100 shares in January as released by FINRA. Its down 23.9% from 1.14M shares previously. With 382,800 avg volume, 2 days are for Vtv Therapeutics Inc – Class A (NASDAQ:VTVT)’s short sellers to cover VTVT’s short positions. The SI to Vtv Therapeutics Inc – Class A’s float is 19.84%. The stock decreased 1.05% or $0.03 during the last trading session, reaching $2.84. About 167,260 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 60.34% since January 11, 2018 and is downtrending. It has underperformed by 60.34% the S&P500. Some Historical VTVT News: 09/05/2018 – VTV THERAPEUTICS INC – SUBGROUP OF MILD ALZHEIMER’S PATIENTS IN PART A OF PHASE 3 STEADFAST STUDY DEMONSTRATED POSITIVE BENEFIT; 31/05/2018 – VTv Therapeutics: Rights for vTv’s PDE4 Inhibitor in China, Other Pacific Rim Territories; 23/04/2018 – DJ vTv Therapeutics Inc Class A, Inst Holders, 1Q 2018 (VTVT); 09/04/2018 – VTV: PART A OF STEADFAST PHASE 3 DIDN’T MEET EFFICACY ENDPOINT; 09/04/2018 – VTV THERAPEUTICS – WILL CONTINUE TO EVALUATE SUBSET DATA FROM PART A AND DATASET FROM PART B OF STEADFAST STUDY OVER COMING WEEKS; 09/04/2018 – VTv Therapeutics Discontinuing Current Clinical Studies Involving Azeliragon; 09/04/2018 – The drumbeat of Alzheimer’s PhIII failures continues as vTv drug is outperformed by a placebo $VTVT go kerplunk; 29/05/2018 – OPUS GROUP AB (PUBL) – VTV NORTE AND VTV METRO WILL CONTINUE TO OPERATE UNDER SAME NAMES, AND WITH SAME HIGHLY EXPERIENCED MANAGEMENT TEAM AND STAFF; 09/05/2018 – VTV THERAPEUTICS TO PRE-SPECIFY NEW SUBGROUP WITH FDA; 09/04/2018 – vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease

More notable recent vTv Therapeutics Inc. (NASDAQ:VTVT) news were published by: which released: “Health Care Sector Update for 12/31/2018: VTVT, ADMP, MBOT, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on December 31, 2018, also with their article: “Health Care Sector Update for 12/28/2018: ALNY,IMMU,APHA,APHA.TO,VTVT – Nasdaq” published on December 28, 2018, published: “Mid-Day Market Update: Crude Oil Up Over 1%; Quantum Shares Spike Higher – Nasdaq” on December 28, 2018. More interesting news about vTv Therapeutics Inc. (NASDAQ:VTVT) were released by: and their article: “38 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” published on January 08, 2019 as well as‘s news article titled: “Healthcare & Tech dominate midday movers – Seeking Alpha” with publication date: December 28, 2018.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $123.37 million. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

Analysts await Royal Gold, Inc. (NASDAQ:RGLD) to report earnings on February, 6. They expect $0.34 earnings per share, down 17.07% or $0.07 from last year’s $0.41 per share. RGLD’s profit will be $22.27M for 61.72 P/E if the $0.34 EPS becomes a reality. After $0.23 actual earnings per share reported by Royal Gold, Inc. for the previous quarter, Wall Street now forecasts 47.83% EPS growth.

Among 2 analysts covering Royal Gold (NASDAQ:RGLD), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Royal Gold had 3 analyst reports since October 10, 2018 according to SRatingsIntel. TD Securities downgraded the stock to “Hold” rating in Friday, November 2 report. The company was maintained on Wednesday, November 14 by Barclays Capital.

Investors sentiment decreased to 0.97 in Q3 2018. Its down 0.15, from 1.12 in 2018Q2. It is negative, as 34 investors sold RGLD shares while 82 reduced holdings. 39 funds opened positions while 74 raised stakes. 48.55 million shares or 0.49% less from 48.79 million shares in 2018Q2 were reported. First Eagle Inv Lc has invested 0.65% in Royal Gold, Inc. (NASDAQ:RGLD). Tradewinds Capital Mgmt Lc has 81 shares for 0% of their portfolio. Tiverton Asset Management Lc, a Delaware-based fund reported 3,427 shares. Panagora Asset invested in 0% or 880 shares. Horizon Kinetics Lc invested in 279,039 shares or 0.52% of the stock. 16,749 are owned by Hartford Mngmt. Janney Cap Mgmt Lc holds 0% in Royal Gold, Inc. (NASDAQ:RGLD) or 5,325 shares. South Dakota Inv Council holds 0.01% of its portfolio in Royal Gold, Inc. (NASDAQ:RGLD) for 3,400 shares. Stevens First Principles Inv Advsr accumulated 5,000 shares. Deutsche Savings Bank Ag reported 156,621 shares. Commerzbank Aktiengesellschaft Fi has invested 0% of its portfolio in Royal Gold, Inc. (NASDAQ:RGLD). Fifth Third State Bank invested in 258 shares. Aperio Gp owns 78,078 shares for 0.03% of their portfolio. Argent holds 0.03% or 3,917 shares. Swiss Commercial Bank owns 113,800 shares.

Since August 15, 2018, it had 3 insider buys, and 0 sales for $347,915 activity. 500 shares were bought by Veenman Sybil E, worth $39,055. Shares for $154,360 were bought by Sokalsky Jamie C.

Royal Gold, Inc. (NASDAQ:RGLD) Institutional Positions Chart